These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 32645082)

  • 1. Medium-term outcomes of sacral neuromodulation in patients with refractory overactive bladder: A retrospective single-institution study.
    Kaaki B; Gupta D
    PLoS One; 2020; 15(7):e0235961. PubMed ID: 32645082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-Term Functional Outcomes of S3 Sacral Neuromodulation for the Treatment of Idiopathic Overactive Bladder.
    Ismail S; Chartier-Kastler E; Perrouin-Verbe MA; Rose-Dite-Modestine J; Denys P; Phé V
    Neuromodulation; 2017 Dec; 20(8):825-829. PubMed ID: 28967986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sacral neuromodulation for refractory overactive bladder after prior intravesical onabotulinumtoxinA treatment.
    Hoag N; Plagakis S; Pillay S; Edwards AW; Gani J
    Neurourol Urodyn; 2017 Jun; 36(5):1377-1381. PubMed ID: 27612039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A prospective, multicenter study of a novel, miniaturized rechargeable sacral neuromodulation system: 12-month results from the RELAX-OAB study.
    Blok B; Van Kerrebroeck P; de Wachter S; Ruffion A; Van der Aa F; Jairam R; Perrouin-Verbe MA; Elneil S
    Neurourol Urodyn; 2019 Feb; 38(2):689-695. PubMed ID: 30592526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Functional results and satisfaction in 44 patients after implantation of a NS3-type sacral neurostimulator for refractory idiopathic overactive bladder followed at 43 months, single-center series].
    Msika J; Kalantan M; Larre S; Leon P
    Prog Urol; 2021 Oct; 31(12):725-731. PubMed ID: 33962849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Remotely programmed sacral neuromodulation for the treatment of patients with refractory overactive bladder: a prospective randomized controlled trial evaluating the safety and efficacy of a novel sacral neuromodulation device.
    Zhang Y; Zhang P; Tian X; Chen G; Li Y; Zhang Y; Xu Z; Wei Z; Zhang W; Ma L; Shi B; Liao L; Wang J
    World J Urol; 2019 Nov; 37(11):2481-2492. PubMed ID: 30809700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cognitive impairment does not impact sacral neuromodulation implant rates for overactive bladder.
    Zillioux J; Lewis KC; Hettel D; Goldman HB; Vasavada SP; Gill BC
    Neurourol Urodyn; 2023 Mar; 42(3):623-630. PubMed ID: 36701189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimal Lead Positioning in Sacral Neuromodulation: Which Factors Are Related to Treatment Outcome?
    Jairam R; Marcelissen T; van Koeveringe G; van Kerrebroeck P
    Neuromodulation; 2017 Dec; 20(8):830-835. PubMed ID: 28877395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Refractory overactive bladder after urethrolysis for bladder outlet obstruction: management with sacral neuromodulation.
    Starkman JS; Duffy JW; Wolter CE; Kaufman MR; Scarpero HM; Dmochowski RR
    Int Urogynecol J Pelvic Floor Dysfunct; 2008 Feb; 19(2):277-82. PubMed ID: 17671752
    [TBL] [Abstract][Full Text] [Related]  

  • 10. What uro-gynecologists should know about sacral neuromodulation (SNM) for the treatment of refractory overactive bladder.
    Oelke M; Addali M; Reisenauer C
    Arch Gynecol Obstet; 2019 May; 299(5):1243-1252. PubMed ID: 30941558
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Refractory overactive bladder patients who chose sacral neuromodulation therapy after failed OnabotulinumtoxinA treatment: A systematic review and meta-analysis.
    Yang G; Xu Y; Qu G; Zhang Y
    PLoS One; 2020; 15(3):e0230355. PubMed ID: 32226049
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Results of a prospective, randomized, multicenter study evaluating sacral neuromodulation with InterStim therapy compared to standard medical therapy at 6-months in subjects with mild symptoms of overactive bladder.
    Siegel S; Noblett K; Mangel J; Griebling TL; Sutherland SE; Bird ET; Comiter C; Culkin D; Bennett J; Zylstra S; Berg KC; Kan F; Irwin CP
    Neurourol Urodyn; 2015 Mar; 34(3):224-30. PubMed ID: 24415559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Sacral neuromodulation in under- and overactive detrusor-quo vadis? : Principles and developments].
    Girtner F; Burger M; Mayr R
    Urologe A; 2019 Jun; 58(6):634-639. PubMed ID: 31139864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sacral neuromodulation in patients with refractory overactive bladder symptoms after failed Botulinum toxin therapy: Results in a large cohort of patients.
    Reekmans M; Janssen JMW; Vrijens DMJ; Smits MAC; van Koeveringe GA; Van Kerrebroeck PEVA
    Neurourol Urodyn; 2021 Jun; 40(5):1120-1125. PubMed ID: 33829519
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sacral neuromodulation for the treatment of overactive bladder: systematic review and future prospects.
    Tilborghs S; De Wachter S
    Expert Rev Med Devices; 2022 Feb; 19(2):161-187. PubMed ID: 35061951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prolonged percutaneous SNM testing does not cause infection-related explanation.
    Amend B; Bedke J; Khalil M; Stenzl A; Sievert KD
    BJU Int; 2013 Mar; 111(3):485-91. PubMed ID: 22738331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term outcomes of sacral neuromodulation for lower urinary tract dysfunction: A 23-year experience.
    Gandhi S; Gajewski JB; Koziarz A; Almutairi S; Ali A; Cox A
    Neurourol Urodyn; 2021 Jan; 40(1):461-469. PubMed ID: 33232534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes of Sacral Nerve Stimulation for Treatment of Refractory Overactive Bladder Among Octogenarians.
    Greenberg DR; Syan R; Young-Lin N; Comiter CV; Enemchukwu E
    Neuromodulation; 2019 Aug; 22(6):738-744. PubMed ID: 31215713
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two-year safety and efficacy outcomes for the treatment of overactive bladder using a long-lived rechargeable sacral neuromodulation system.
    Blok B; Van Kerrebroeck P; de Wachter S; Ruffion A; Van der Aa F; Perrouin-Verbe MA; Elneil S
    Neurourol Urodyn; 2020 Apr; 39(4):1108-1114. PubMed ID: 32243625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of sacral neuromodulation on urological diseases: a multicentric research project.
    Cardarelli S; D'Elia C; Cerruto MA; Curti P; Ostardo E; Signorello D; Pastorello M; Caleffi G; Molon A; Artibani W
    Urologia; 2012; 79(2):90-6. PubMed ID: 22610844
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.